Is Sarepta Therapeutics (SRPT) Undervalued Following New SRP 1003 Preclinical Data?

Sarepta Therapeutics (SRPT) recently shared new preclinical data on its SRP-1003 program for myotonic dystrophy type 1, giving investors fresh information about the depth of its RNA-targeted pipeline.

The fresh SRP-1003 data arrives after a choppy year for Sarepta Therapeutics, with the share price retreating 12.9% year to date but gaining 16.9% over 90 days. Over a longer horizon, the 1-year total shareholder return has declined 17.4% and the 3-year total shareholder return has dropped 82.7%, indicating that recent momentum is improving off a much weaker long-term base.

Spot opportunities across RNA and rare-disease plays by scanning our hand-picked 37 healthcare AI stocks alongside Sarepta Therapeutics.

The rebound in Sarepta Therapeutics after a rough multi year stretch could signal that investors are refocusing on the underlying RNA and gene therapy portfolio rather than on sentiment swings alone. How does that translate into today’s valuation setup?

Most Popular Narrative: 15% Undervalued

On the most widely followed view, Sarepta Therapeutics screens as modestly undervalued, with a narrative fair value of $21.73 against the latest close at $18.56. The gap between price and expectations is clear before even looking at the science and cash flows behind it.

Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.

See why 42 investors see Sarepta Therapeutics as 15% undervalued.

Result: Fair Value of $21.73 (UNDERVALUED)

Still, the narrative around Sarepta Therapeutics can change quickly if ELEVIDYS safety concerns resurface or if exon skipping competitors pressure Duchenne cash flows sooner than expected.

Find out about the key risks to this Sarepta Therapeutics narrative.

Next Steps

Mixed messages in the Sarepta Therapeutics story so far, right? Act while the data is fresh and weigh those 1 or more risks against the 1 or more potential upsides by reviewing the 2 key rewards and 1 important warning sign.

Hunting Beyond Sarepta Therapeutics For Fresh Ideas

Do not stop at Sarepta Therapeutics. Broaden your watchlist with focused stock ideas built from hard data so you can act before the crowd catches on.

• Target potential mispricings by scanning a focused group of 33 high quality undervalued stocks that combine quality fundamentals with markdown style price tags.
• Pursue income stability by studying a curated set of 7 dividend fortresses that aim to pair strong yields with resilient cash generation.
• Prioritise resilience by reviewing a 31 resilient stocks with low risk scores that concentrates on sturdier balance sheets and calmer volatility profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com